Emicizumab also can yield clinically relevant improvements in joint fitness in patients with hemophilia, according to consequences provided at the 61st American Society of Hematology (ASH) Annual Meeting in Orlando, Florida.
Previous outcomes from the section 3 Haven 3 trial (ClinicalTrials.gov Identifier: NCT02847637) indicate that emicizumab has a favorable protection profile and has led to discounts in joint bleeds. In this analysis, researchers tested the outcome of emicizumab prophylaxis on bone and joint fitness.
Joint health changed into assessed employing the hemophilia joint fitness ranking (HJHS) as a measure, wherein minimize scores imply larger joint health; 107 patients with hemophilia A were evaluated at baseline and at week 49 of prophylaxis. In addition, distinctive biomarkers of bone health were evaluated in 117 patients with hemophilia A at baseline and after 3, 6, 12, and 18 months of prophylaxis. Of these patients, 78 were also covered in the HJHS assessment.
At baseline, patients who had formerly acquired point VIII prophylaxis and who had no target joints pronounced minimize HJHS scores.
In patients who had 1 or more objective joints, total HJHS reduced a median of 2.25 points from baseline to week 49.
Levels of maximum bone and joint biomarkers at baseline were identical to published degrees in healthy individuals, however there become giant variability. Baseline biomarker levels were identical among patients receiving point VIII prophylaxis and patients receiving on-demand treatment, as well as among patients with or without target joints. No huge transformations were accompanied all over the look at period. However, a expertise arrangement between cartilage oligomeric matrix protein and baseline HJHS become observed (Pearson correlation coefficient, 0.46; P =.0001).
“Based on extra investigations, this correlation can also be considerably driven by means of age,” famous Anna Kiialainen, PhD, of F Hoffmann-La Roche Ltd in Switzerland, in her presentation.
“Clinically applicable innovations in HJHS were observed for HAVEN 3 participants with goal joints after as little as 48 weeks of emicizumab,” Dr Kiialainen concluded. “Additional data are needed to higher take into account the long-term end result of emicizumab prophylaxis on bone and joint fitness.”
Disclosures: Some authors have declared affiliations with the pharmaceutical industry, including employment. Please refer to the usual look at for a complete list of disclosures.
Kiialainen A, Miggli M, Kempton CL, et al. Bone and joint health markers in persons with hemophilia A (PwHA) treated with emicizumab in HAVEN 3.
Oral presentation at: 61st ASH Annual Meeting and Exposition; December 7-10, 2019; Orlando, FL. Abstract 626.
Next post in ASH 2019